Product
Cebranopadol
Aliases
Cebranopadol 1000 µg, Cebranopadol 600 µg, Cebranopadol 800 µg, Experimental
3 clinical trials
3 indications
Indication
PainIndication
AbuseIndication
MedicationClinical trial
Randomized, Double-blind, Four Period, Six-treatment, Double-dummy, Placebo Controlled, Partial-crossover Study to Explore and Compare the Ventilatory Response to Hypercapnia (VRH) of Cebranopadol, Oxycodone, and Placebo in Healthy SubjectsStatus: Completed, Estimated PCD: 2023-03-30
Clinical trial
A Double-Blind, Randomized, Crossover Study to Assess the Abuse Potential of Intranasal Cebranopadol Compared to Oxycodone and Placebo in Healthy, Nondependent Recreational Opioid UsersStatus: Not yet recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled Study to Evaluate the Efficacy and Safety of Cebranopadol for the Treatment of Moderate to Severe Acute Pain After Primary Unilateral BunionectomyStatus: Not yet recruiting, Estimated PCD: 2024-11-01